Dare Bioscience, Inc. current report, 01 December 2022

Dare Bioscience, Inc. - 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Dare Bioscience, Inc. (DARE) on December 5, 2022, reporting an event that occurred on December 1, 2022. The company is a biotechnology firm focused on developing long-acting reversible contraceptives (LARC), specifically the DARE-LARC1 program.

Key Financial Metrics

The filing reports a specific non-dilutive funding event rather than comprehensive financial statements.

  • Grant Payment Received: Approximately $4.4 million from the Bill & Melinda Gates Foundation.
  • Cumulative Grant Funding: Approximately $23.8 million received to date under the Grant Agreement.
  • Total Potential Grant Value: Up to $48.95 million available over the grant period.
  • Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these metrics.

Material Changes

The primary material change is the receipt of the $4.4 million grant payment, increasing the total non-dilutive funding received under the existing agreement with the Bill & Melinda Gates Foundation. This funding supports technology development and preclinical activities for the DARE-LARC1 program.

Outlook, Risks, and Contingencies

Future payments under the Grant Agreement are contingent upon the achievement of specified development and reporting milestones for the DARE-LARC1 program during the Grant Period (June 30, 2021, to November 1, 2026). The funding is designated for nonclinical proof of principle studies.

Investor Verification Checklist

  • Verify the specific development milestones required to unlock the remaining potential funding of approximately $25.15 million.
  • Confirm the current cash runway and burn rate in the company's most recent 10-Q or 10-K to assess the impact of this $4.4 million injection.
  • Review the status of the DARE-LARC1 nonclinical proof of principle studies to gauge the likelihood of meeting future grant contingencies.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.